Andrzej Budaj

Lipoprotein‐Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease

P. Pais, Á. Avezum, A. Parkhomenko, 2016, Journal of the American Heart Association.